The stock of Atara Biotherapeutics Inc (NASDAQ:ATRA) is a huge mover today! About 163,462 shares traded hands. Atara Biotherapeutics Inc (NASDAQ:ATRA) has declined 1.79% since April 13, 2016 and is downtrending. It has underperformed by 5.72% the S&P500.
The move comes after 9 months negative chart setup for the $574.98M company. It was reported on Nov, 15 by Barchart.com. We have $18.43 PT which if reached, will make NASDAQ:ATRA worth $51.75 million less.
Atara Biotherapeutics Inc (NASDAQ:ATRA) Ratings Coverage
Out of 6 analysts covering Atara Biotherapeutics (NASDAQ:ATRA), 4 rate it a “Buy”, 2 “Sell”, while 0 “Hold”. This means 67% are positive. Atara Biotherapeutics has been the topic of 13 analyst reports since September 9, 2015 according to StockzIntelligence Inc. Canaccord Genuity initiated Atara Biotherapeutics Inc (NASDAQ:ATRA) rating on Wednesday, September 9. Canaccord Genuity has “Buy” rating and $80 price target. Citigroup maintained the shares of ATRA in a report on Monday, August 22 with “Sell” rating. The company was initiated on Friday, September 25 by JMP Securities. The firm earned “Market Outperform” rating on Wednesday, March 9 by JMP Securities. William Blair initiated the shares of ATRA in a report on Friday, October 9 with “Outperform” rating. The stock of Atara Biotherapeutics Inc (NASDAQ:ATRA) has “Sell” rating given on Friday, August 19 by Citigroup. Goldman Sachs downgraded the stock to “Sell” rating in Thursday, September 15 report. JMP Securities maintained the stock with “Market Outperform” rating in Tuesday, December 15 report. The firm has “Neutral” rating by Goldman Sachs given on Wednesday, November 18. Jefferies reinitiated the shares of ATRA in a report on Monday, October 24 with “Buy” rating.
According to Zacks Investment Research, “Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing therapeutics for serious unmet medical needs, with an initial focus on muscle wasting conditions and oncology. The company’s lead programs are focused on myostatin and activin, members of the TGF-beta family of proteins that have demonstrated the potential to have therapeutic benefit in a number of clinical indications. Its lead product candidate is PINTA 745, which is in a Phase II clinical trial for the treatment of protein-energy wasting in end-stage renal disease patients. Atara Biotherapeutics, Inc. is headquartered in Brisbane, California.”
Insitutional Activity: The institutional sentiment increased to 3.36 in Q2 2016. Its up 2.20, from 1.16 in 2016Q1. The ratio improved, as 6 funds sold all Atara Biotherapeutics Inc shares owned while 8 reduced positions. 7 funds bought stakes while 40 increased positions. They now own 43.46 million shares or 112.65% more from 20.44 million shares in 2016Q1.
Ubs Asset Mgmt Americas last reported 0.03% of its portfolio in the stock. Redmile Group Ltd Liability Company holds 2.41 million shares or 5.18% of its portfolio. Moreover, Cormorant Asset Management Limited Co has 0.6% invested in Atara Biotherapeutics Inc (NASDAQ:ATRA) for 186,460 shares. Arrowpoint Asset Mngmt Ltd reported 1.25M shares or 0.57% of all its holdings. Pnc Fin Serv holds 6,563 shares or 0% of its portfolio. Jpmorgan Chase And has 0% invested in the company for 90,135 shares. Fmr Ltd Liability Company last reported 0.01% of its portfolio in the stock. Deutsche National Bank & Trust Ag last reported 9,779 shares in the company. California State Teachers Retirement System reported 48,704 shares or 0% of all its holdings. Credit Suisse Ag has invested 0% of its portfolio in Atara Biotherapeutics Inc (NASDAQ:ATRA). Harbourvest Ltd reported 10,543 shares or 0.11% of all its holdings. Blackrock Lc has 10,186 shares for 0% of their US portfolio. Blackrock Fund Advsr owns 913,922 shares or 0% of their US portfolio. Moreover, Schwab Charles Investment has 0% invested in Atara Biotherapeutics Inc (NASDAQ:ATRA) for 66,295 shares. Brown Brothers Harriman And Company has 0% invested in the company for 126 shares.
Insider Transactions: Since May 16, 2016, the stock had 0 insider buys, and 13 sales for $1.89 million net activity. 1,184 shares with value of $18,897 were sold by Gallagher Carol Giltner on Monday, May 16. 5,395 Atara Biotherapeutics Inc (NASDAQ:ATRA) shares with value of $85,079 were sold by MCGRATH JOHN. $219,648 worth of Atara Biotherapeutics Inc (NASDAQ:ATRA) was sold by Ciechanover Isaac E.. On Monday, May 16 Soffer Gad sold $86,344 worth of the stock or 5,427 shares. Haqq Christopher sold $30,041 worth of Atara Biotherapeutics Inc (NASDAQ:ATRA) on Monday, August 15. Shares for $62,918 were sold by Clark Mitchall G..
More recent Atara Biotherapeutics Inc (NASDAQ:ATRA) news were published by: Marketwatch.com which released: “Atara Biotherapeutics stock price target cut to $16 from $23 at Goldman Sachs” on October 17, 2014. Also Fool.com published the news titled: “Why Atara Biotherapeutics Inc. Shares Are Getting Mauled Today” on December 14, 2015. Quotes.Wsj.com‘s news article titled: “News Atara Biotherapeutics Inc.ATRA” with publication date: July 19, 2014 was also an interesting one.
ATRA Company Profile
Atara Biotherapeutics, Inc., incorporated on August 22, 2012, is a clinical-stage biopharmaceutical company. The Firm is focused on developing therapies for patients with severe and life-threatening diseases. The Company’s segment is the business of developing and commercializing therapeutics. The Firm has approximately two groups of product candidates, such as allogeneic or third-party derived antigen-specific T-cells, and molecularly targeted biologics. The Company’s T-cell product candidates arise from a platform technology designed to produce off-the-shelf, partially human leukocyte antigen (HLA) matched cellular therapeutics utilizing cytotoxic T lymphocytes (CTLs). The Company’s T-cell product candidates target viral or cancer-specific antigens, and are designed to harness the body’s immune system to counteract specific viral infections and cancers. The Company’s T-cell product candidates include Epstein Barr Virus (EBV)-CTL, which is in Phase II clinical trials for malignancies associated with EBV, including EBV-associated post-transplant lymphoproliferative disorders (EBV-PTLD); cytomegalovirus (CMV)-CTL, which is in Phase II clinical trials for CMV, and Wilms Tumor 1 (WT1)-CTL, which targets cancers expressing the antigen WT1 and is in Phase I clinical trials.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.